Maxime Verhoeven

36 Chapter 2 SUPPLEMENTARY FILE Supplementary Data S1: Research question (PICO) and search terms P= early RA patients I= treatment with a bDMARD (with or without a csDMARD) or starting with a csDMARDs in addition to glucocorticoids in moderate-high dose or starting with a targeted small molecule, with or without a csDMARDs or combination csDMARDs therapy C= control therapy (csDMARDs monotherapy in a step-up strategy, low-moderate GCs for short term) O= remission(as defined by (validated disease activity indices or Boolean definition) The following key search were used in title and/or abstract; ‘early’ OR ‘dmard-naive’ OR ‘treatment-naive’ OR ‘dmard naive’ OR ‘new onset’ OR ‘new-onset’ AND ‘rheumatoid arthritis’ OR ‘ra’ OR ‘arthritis’ OR ‘arthritides’ OR ‘polyarhritis’ OR ‘polyarthritides’ AND ‘disease modifying’ OR ‘disease-modifying’ OR ‘antirheumatic’ OR ‘anti-rheumatic’ OR ‘anti rheumatic’ OR ‘biological’ OR ‘csdmards’ OR ‘csdmard’ OR ‘bdmards’ OR ‘bdmard’ OR ‘mtx’ OR ‘methotrexate’ OR ‘glucocorticoid’ OR ‘gc’ OR ‘prednisone’ OR ‘prednisolone’ OR ‘steroid’ OR ‘corticosteroid’ OR ‘adalimumab’ OR ‘certolizumab’ OR ‘etanercept’ OR ‘golimumab’ OR ‘infliximab’ OR ‘abatacept’ OR ‘rituximab’ OR ‘tocilizumab’ OR ‘sulfasalazine’ OR ‘Sulphasalazine’ OR ‘salazopyrin’ OR ‘hydroxychloroquine’ OR ‘leflunomide’ OR ‘tofacitinib’ OR ‘baricitinib’ OR ‘jak’ OR ‘janus-associated kinase’ OR ‘jak inhibitor’ OR ‘jak-inhibitor’ OR ‘plaquenil’ AND ‘remission’ OR ‘das28’ OR ‘cdai’ OR ‘sdai’ OR ‘disease activity’ OR ‘effectiveness’ OR ‘efficacy’ OR ‘response’.